Targeting KRAS in pancreatic cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), has a poor prognosis due to late detection and limited therapeutic options.
• The Kirsten rat sarcoma virus (KRAS) oncogene is frequently mutated in PDAC (up to 90%), making it a key therapeutic target.

Purpose of the Study:

• To review the challenges and advancements in targeting KRAS mutations in pancreatic cancer.
• To highlight novel therapeutic strategies for prevalent KRAS mutations in PDAC.

Main Methods:

• Analysis of current literature on KRAS mutations in PDAC.
• Review of emerging KRAS-targeted therapies and indirect inhibition strategies.

Main Results:

• Common KRAS mutations in PDAC (G12D, G12V, G12R) are not targeted by existing KRAS G12C inhibitors like Sotorasib.
• KRAS G12C mutations, though targetable, are rare in PDAC (2-3%).
• New inhibitors like MRTX1133 targeting KRAS G12D are in clinical trials, and indirect targeting via Son of Sevenless 1 (SOS1) inhibition is under development.

Conclusions:

• Emerging KRAS-directed therapies and indirect targeting strategies show promise for addressing the most common KRAS mutations in PDAC.
• These novel approaches have the potential to significantly improve treatment outcomes for pancreatic cancer patients.